Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference

Tempus AI's diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200. Read why TEM ...

MIT’s new ‘recursive’ framework lets LLMs process 10 million tokens without context rot

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
IEEE

Outlier-Aware Recursive Instantaneous Minimum Error Entropy Algorithm

Abstract: The minimum error entropy (MEE) criterion closely relies on the quadratic information potential (QIP) estimates of Renyi’s entropy. Nevertheless, the ...
IEEE

Recursive Identification Based on Local Likelihood Function with Binary-Valued Observations

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...
Hosted on MSN

Forget Recursion Pharmaceuticals stock. This is a much better buy.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Hosted on MSN

Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...
Search Engine Land

Google algorithm updates 2025 in review: 3 core updates and 1 spam update

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...
Insider Monkey

Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...